|
[posting]37970224[/posting]Hallo zusammen. Ich finde auch, dass es die eine oder andere Unklarheit bei Magforce gibt, aber keine wissenschaftlichen Publikationen - das stimmt nicht ganz. 1)1: Biomaterials. 2008 Oct 9. [Epub ahead of print] LinksPost-mortem studies in glioblastoma patients treated with thermotherapy using magnetic nanoparticles. van Landeghem FK, Maier-Hauff K, Jordan A, Hoffmann KT, Gneveckow U, Scholz R, Thiesen B, Brück W, von Deimling A.Institute of Neuropathology, Charité - Universitätsmedizin Berlin, CVK, 13353 Berlin, Germany. Patients with glioblastoma multiforme (GBM), the most common primary brain tumor in adults, have still a poor prognosis though new strategies of radio- and chemotherapy have been developed. Recently, our group demonstrated the feasibility, tolerability and anti-tumoral effects of a newly developed therapeutic approach, termed thermotherapy using magnetic nanoparticles or magnetic fluid hyperthermia (MFH), in a murine model of malignant glioma. Currently, the efficacy of MFH is being evaluated in a phase II study. Here, we report on post-mortem neuropathological findings of patients with GBM receiving MFH. In brain autopsies the installed magnetic nanoparticles were dispersed or distributed as aggregates within geographic tumor necroses, restricted in distribution to the sites of instillation. Therefore, our results underscore the need for multiple trajectories of instillation. The typical GBM necrosis with pseudopalisading was free of particles. Dispersed particles and particle aggregates were phagocytosed mainly by macrophages whereas glioblastoma cells showed an uptake to a minor extent. MFH therapy further promotes uptake of nanoparticles in macrophages, likely as a consequence of tumor inherent and therapy induced formation of necrosis with subsequent infiltration and activation of phagocytes. We did not observe bystander effects of MFH such as sarcomatous tumour formation, formation of a sterile abscess or foreign body giant cell reaction. Furthermore, all patients did not present any clinical symptoms related to possible adverse effects of MFH. 2)J Nanosci Nanotechnol. 2007 Dec;7(12):4604-6.LinksMagnetic nanoparticles for intracranial thermotherapy. Jordan A, Maier-Hauff K. MagForce Nanotechnologies AG, Charité Universitätsmedizin Berlin, Center of Biomedical Nanotechnology (CBN), Berlin, Germany. Thermotherapy using magnetic nanoparticles, also termed nanotherapy, is a new therapeutic concept in which tumor cells are damaged via local heat application. The principle of this method is direct injection of a magnetic fluid into a tumor and its subsequent heating in an alternating magnetic field. The heat created this way (thermotherapy) causes either direct damage to the tumor cells (depending on temperature and reaction time) or make cells more susceptible to accompanying radio- or chemotherapy. The results of a feasibility trial (phase I) on the treatment of brain tumors (glioblastoma multiforme) are presented. 3)Int J Hyperthermia. 2008 Sep;24(6):467-74. Links Clinical applications of magnetic nanoparticles for hyperthermia.Thiesen B, Jordan A. MagForce Nanotechnologies AG, Berlin, Germany. bthiesen@magforce.com Magnetic fluids are increasingly used for clinical applications such as drug delivery, magnetic resonance imaging and magnetic fluid hyperthermia. The latter technique that has been developed as a cancer treatment for several decades comprises the injection of magnetic nanoparticles into tumors and their subsequent heating in an alternating magnetic field. Depending on the applied temperature and the duration of heating this treatment either results in direct tumor cell killing or makes the cells more susceptible to concomitant radio- or chemotherapy. Numerous groups are working in this field worldwide, but only one approach has been tested in clinical trials so far. Here, we summarize the clinical data gained in these studies on magnetic fluid induced hyperthermia. 4) J Neurooncol. 2007 Jan;81(1):53-60. Epub 2006 Jun 14. LinksIntracranial thermotherapy using magnetic nanoparticles combined with external beam radiotherapy: results of a feasibility study on patients with glioblastoma multiforme. Maier-Hauff K, Rothe R, Scholz R, Gneveckow U, Wust P, Thiesen B, Feussner A, von Deimling A, Waldoefner N, Felix R, Jordan A. Department of Neurosurgery, Bundeswehrkrankenhaus, Berlin, Germany. KlausMaierHauff@bundeswehr.org We aimed to evaluate the feasibility and tolerability of the newly developed thermotherapy using magnetic nanoparticles on recurrent glioblastoma multiforme. Fourteen patients received 3-dimensional image guided intratumoral injection of aminosilane coated iron oxide nanoparticles. The patients were then exposed to an alternating magnetic field to induce particle heating. The amount of fluid and the spatial distribution of the depots were planned in advance by means of a specially developed treatment planning software following magnetic resonance imaging (MRI). The actually achieved magnetic fluid distribution was measured by computed tomography (CT), which after matching to pre-operative MRI data enables the calculation of the expected heat distribution within the tumor in dependence of the magnetic field strength. Patients received 4-10 (median: 6) thermotherapy treatments following instillation of 0.1-0.7 ml (median: 0.2) of magnetic fluid per ml tumor volume and single fractions (2 Gy) of a radiotherapy series of 16-70 Gy (median: 30). Thermotherapy using magnetic nanoparticles was tolerated well by all patients with minor or no side effects. Median maximum intratumoral temperatures of 44.6 degrees C (42.4-49.5 degrees C) were measured and signs of local tumor control were observed. In conclusion, deep cranial thermotherapy using magnetic nanoparticles can be safely applied on glioblastoma multiforme patients. 5)Actas Urol Esp. 2007 Jun;31(6):660-7.Links [Thermal therapy of prostate cancer using magnetic nanoparticles][Article in Spanish] Johannsen M, Gneveckow U, Taymoorian K, Cho CH, Thiesen B, Scholz R, Waldöfner N, Loening SA, Wust P, Jordan A.Department of Urology, Campus Mitte, Charité-Universitätsmedizin Berlin, Alemania. manfred.johannsen@charite.de A novel method of interstitial heating using magnetic nanoparticles and a direct injection technique has been evaluated in human cancers in recent clinical trials. In prostate cancer, this approach was investigated in two separate phase-I-studies, employing magnetic nanoparticle thermotherapy alone and in combination with permanent seed brachytherapy. The feasibility and good tolerability was shown in both trials, using the first prototype of a magnetic field applicator. As with any other heating technique, this novel approach requires specific tools for planning, quality control and thermal monitoring, based on appropriate imaging and modelling techniques. In these first clinical trials, a newly developed method for planning and non-invasive calculations of the 3-dimensional temperature distribution based on computed tomography could be validated. Limiting factors of this approach at present are patient discomfort at high magnetic field strengths and suboptimal intratumoral distribution of nanoparticles. Until these limitations will be overcome and thermal ablation can safely be applied as a monotherapy, this treatment modality is being evaluated in combination with irradiation in patients with localized prostate cancer. Die Veröffentlicheungen findet ihr unter http://www.pubmed.de/data/nlm.link.html Für Prof. Maier-Hauff 24 Artikel, 4 über Nanotherapie Für A Jordan ist das schwieriger, da gibt es mehrere Namensvettern. Aber z.B. Modification of Aminosilanized Superparamagnetic Nanoparticles: Feasibility of Multimodal Detection Using 3T MRI, Small Animal PET, and Fluorescence Imaging. Stelter L, Pinkernelle JG, Michel R, Schwartländer R, Raschzok N, Morgul MH, Koch M, Denecke T, Ruf J, Bäumler H, Jordan A, Hamm B, Sauer IM, Teichgräber U. Mol Imaging Biol. 2009 Jul 7. [Epub ahead of print] PMID: 19582510 [PubMed - as supplied by publisher] Tracking of primary human hepatocytes with clinical MRI: initial results with Tat-peptide modified superparamagnetic iron oxide particles. Morgul MH, Raschzok N, Schwartlander R, Vondran FW, Michel R, Stelter L, Pinkernelle J, Jordan A, Teichgraber U, Sauer IM. Int J Artif Organs. 2008 Mar;31(3):252-7. PMID: 18373319 [PubMed - indexed for MEDLINE] 18F-FET PET for planning of thermotherapy using magnetic nanoparticles in recurrent glioblastoma. Plotkin M, Gneveckow U, Meier-Hauff K, Amthauer H, Feussner A, Denecke T, Gutberlet M, Jordan A, Felix R, Wust P. Int J Hyperthermia. 2006 Jun;22(4):319-25. PMID: 16754352 [PubMed - indexed for MEDLINE] Nanotechnology and consequences for surgical oncology Jordan A. Kongressbd Dtsch Ges Chir Kongr. 2002;119:821-8. German. PMID: 12704931 [PubMed - indexed for MEDLINE Unter der Suche Jordan A und Charite finden sich 26 Arbeiten. Also es gibt schon Veröffentlichungen, wenn auch nicht besonders viele. Schwerer beurteilbar finde ich schon die Sache, Probanden mit Hilfe einer Krankenkasse einzuwerben. Letztendlich hilft das aber alles nicht weiter - entweder es klappt oder es geht schief Alos viel Glück |
|
| aus der Diskussion: | MAGFORCE - da geht doch was?! |
| Autor (Datum des Eintrages): | herbert123 (13.09.09 19:33:20) |
| Beitrag: | 92 von 4,776 (ID:37970489) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |